Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials by Steve, Bain
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
Diabetes Therapy
                                  
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa45467
_____________________________________________________________
 
Paper:
Fulcher, G., Mehta, R., Fita, E., Ekelund, M. & Bain, S. (2019).  Efficacy and Safety of IDegAsp Versus BIAsp 30, Both
Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled
BOOST Trials. Diabetes Therapy, 10(1), 107-118.
http://dx.doi.org/10.1007/s13300-018-0531-0
 
 
 
 
 
 
Released under the terms of a Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC).
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/ 
 ORIGINAL RESEARCH
Efficacy and Safety of IDegAsp Versus BIAsp 30, Both
Twice Daily, in Elderly Patients with Type 2 Diabetes:
Post Hoc Analysis of Two Phase 3 Randomized
Controlled BOOST Trials
Greg Fulcher . Roopa Mehta . Edmond G. Fita . Magnus Ekelund .
Stephen C. Bain
Received: August 6, 2018 / Published online: November 24, 2018
 The Author(s) 2018
ABSTRACT
Introduction: The majority of elderly patients
(C 65 years of age) with type 2 diabetes mellitus
(T2DM) will eventually require insulin therapy,
but they are particularly vulnerable to hypo-
glycemia and challenging to treat. Insulin
degludec/insulin aspart (IDegAsp) is a novel co-
formulation of 70% insulin degludec and 30%
insulin aspart administered in a single injection,
either once or twice daily with main meals.
Methods: A combined analysis of the phase 3
BOOST INTENSIFY PREMIX I (NCT01009580)
and BOOST INTENSIFY ALL (NCT01059812) tri-
als has previously reported lower rates of hypo-
glycemia during the maintenance period in
patients with T2DM treated with IDegAsp twice
daily (BID) versus biphasic insulin aspart 30
(BIAsp 30) BID. This post hoc analysis examined
the safety and efficacy of IDegAspversus BIAsp 30
in elderly patients from the global population of
these two trials, and also from the Japanese
cohort of BOOST INTENSIFY ALL.
Results: Change in HbA1c was similar for
IDegAsp versus BIAsp 30 (p[ 0.5). Compared
with BIAsp 30, IDegAsp resulted in significant
reductions in fasting plasma glucose
(p \0.0001), numerically lower rates of overall
and nocturnal hypoglycemia (global estimated
rate ratios: 0.92 [0.67; 1.26]95% confidence interval
[CI], p = 0.5980 and 0.67 [0.39; 1.18]95% CI,
p = 0.1676, respectively), and a significantly
lower total daily insulin dose at end of trial (glo-
bal estimated treatment difference 0.79 [0.73;
0.87]95% CI, p \0.0001) in elderly patients.
Conclusion: The results described here are
consistent with those of the overall trial popu-
lations, demonstrating that IDegAsp BID is
efficacious in elderly patients and suggesting
that there is no need for special safety
precautions.
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PLAIN LANGUAGE SUMMARY
IDegAsp is a new insulin therapy for people
with diabetes. It is a combination of two
insulins: insulin degludec (IDeg) and insulin
aspart (IAsp). Previous studies have compared
the IDegAsp combination with biphasic IAsp
30 (a premixed insulin therapy related to IAsp).
These studies have shown that IDegAsp
improves blood glucose levels with a low risk
of harmful side effects. This study examined
whether IDegAsp had the same positive effect
on people who are aged 65 years or older. This
age group is less well represented in clinical
trials compared with younger adults, so this
study pooled together elderly populations from
two trials. Results showed that IDegAsp also
improved blood glucose levels with a low risk
of harmful side effects in elderly patients, and
suggests that IDegAsp can be used in elderly
people with diabetes just as it is used in
younger adults.
INTRODUCTION
The overall goal of type 2 diabetes mellitus
(T2DM) management is to achieve good gly-
cemic control while avoiding the adverse events
(AEs) associated with diabetes progression and
diabetic therapy.Additional challengesmayarise
when treating diabetes in elderly patients, par-
ticularly at the stage of insulin initiation [1, 2].
Fear of hypoglycemia is a commonly cited
barrier to insulin initiation in patients of all ages
[3, 4], buthypoglycemia isofparticular concern in
the elderlypopulation (definedhere as C 65 years
of age). Elderly patients are more susceptible to
hypoglycemia because aging is accompanied by
an increased risk of impaired counter-regulatory
responses to hypoglycemia [5, 6]. Hypoglycemic
episodes in elderly patients have also been asso-
ciated with an increased risk of fall-related events
[7] and also of dementia [8, 9] compared with
patients who did not experience hypoglycemia.
Consequently, achieving tight glycemic control
in elderly patients while avoiding hypoglycemia
is of critical importance, although frequently
challenging [10].
The majority of elderly patients with a longer
duration of T2DM require, or will require at
some point, insulin therapy to achieve glycemic
control; however, insulin therapy is often
underutilized in this population for the reasons
described above [11]. Reducing the risk of
hypoglycemia is an important focus of T2DM
management and, thus, therapy design.
Long-acting (basal) and rapid-acting (bolus)
insulin analogs were developed to provide a
more physiological insulin action profile com-
pared with human insulins [12]. Basal–bolus
regimens can effectively control postprandial
and fasting hyperglycemia; however, this
involves multiple daily injections, which are
another patient-perceived barrier to insulin
initiation/intensification [3, 13, 14]. Although
the benefit of convenience with premixed
insulin compared with a basal–bolus regimen is
attractive to elderly patients, traditional pre-
mixed insulin can result in an increased risk of
hypoglycemia versus basal–bolus therapy [15],
and—as mentioned above—this is particularly
deleterious in the elderly population [5, 13, 16].
Insulin degludec/insulin aspart (IDegAsp;
Ryzodeg,NovoNordiskA/S, Søborg,Denmark) is
thefirst co-formulationof these two insulins, 70%
insulin degludec (IDeg) and 30% insulin aspart
(IAsp), in a single injection, and is administered
once or twice daily with main meals [17]. Impor-
tantly, the molecular properties of IDegAsp are
such that the mechanism of action of each
monocomponent remains unchanged and their
distinct pharmacokinetic (PK)/pharmacody-
namic (PD) properties are preserved in co-formu-
lation, as well as following injection.
The basal component, IDeg, has a flat PK
profile over 24 h and, at steady state, provides a
stable, long-lasting, glucose-lowering effect,
whereas the bolus component, IAsp, has a rapid
onset of action and reduces glucose excursions
at mealtimes [17]. Studies have shown that
these PK/PD properties are preserved across
special patient populations [18]. A glucose
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clamp study demonstrated that PD properties of
IDegAsp, following once- or twice-daily dosing,
were consistent across younger and elderly
adults [19]. While previous findings have sug-
gested that variables such as race and ethnicity
may influence the pharmacological properties
of rapid- and long-acting insulin analogs [20], a
single-dose, euglycemic glucose clamp study
demonstrated that the distinct basal and pran-
dial components of IDegAsp that have been
described in Caucasian populations are also
observed in Japanese patients with type 1 dia-
betes mellitus (T1DM) [21]. Therefore, from a
pharmacological perspective, these studies sug-
gest that the action of IDegAsp is similar in
populations of different ages and races [18].
The IDegAsp clinical trial program (BOOST)
builds on that of IDeg [22–29] and demonstrates
the efficacy and safety profiles of IDegAsp in the
treatment of patients with T1DM and T2DM
[30–32]. Global findings from the overall pop-
ulation of the BOOST clinical trial program
suggest that IDegAsp would benefit elderly
patients. For example, a combined analysis of
two pivotal phase 3a trials (BOOST INTENSIFY
PREMIX I [NCT01009580] and BOOST INTEN-
SIFY ALL [NCT01059812]) has previously
reported lower rates of hypoglycemia during the
maintenance period in patients with T2DM
treated with IDegAsp twice daily versus biphasic
insulin aspart 30 (BIAsp 30) twice daily [33].
The clinical outcomes of treatment with IDe-
gAspcomparedwith thatofBIAsp30canbepartly
explained by their pharmacokinetic/pharmaco-
dynamic properties. In contrast with the glucose-
loweringprofile of IDegAsp,which consists of two
distinct phases of action, the glucose-lowering
effects of the soluble and protaminated fractions
of BIAsp 30 overlap at approximately 6 h after
dosing. This ‘‘shoulder effect’’ is partly responsible
for the day-to-day variability in glycemic control
observed with the intermediate-acting BIAsp 30
[18]. A rapid increase in serum concentration is
observed after BIAsp 30 administration (maxi-
mum concentration reached in 2.1–2.6 h), fol-
lowed by a gradual decline [34]. Appropriate
timing of the second administration to ensure
adequate insulin concentrations throughout the
day and night and avoid episodes of hypo- or
hyperglycemia is important.
This manuscript presents a post hoc pooled
subanalysis of the elderly population from these
two trials. In addition, a subanalysis was per-
formed on the Japanese population of BOOST
INTENSIFY ALL, because elderly Japanese
patients of BOOST INTENSIFY ALL comprised
the largest elderly subpopulation in these two
trials [31, 32]. In addition, the Japanese popu-
lation is of special interest for investigation, as
Japan has a large and growing elderly popula-
tion [35], and IDegAsp use is greater in Japan
than in any other country.
This post hoc analysis aimed to evaluate the
safety and efficacy of IDegAsp in elderly patients
with T2DM.
METHODS
Trial Design
The trial designs for BOOST INTENSIFY PREMIX I
(global population) and BOOST INTENSIFY ALL
(pan-Asian population) have been described
previously [31, 32] and are similar (Fig. 1). Both
trials were phase 3a, randomized, parallel, open-
label, multicenter trials with an intent-to-treat
design and a duration of 26 weeks.
Participants
In BOOST INTENSIFY PREMIX I, eligible
patients had been treated previously with either
premixed or self-mixed insulin (once or twice
daily) ± oral antidiabetic drugs (metformin,
sulfonylureas, glinides, alpha-glucosidase inhi-
bitors, dipeptidyl peptidase-4 inhibitors, and
pioglitazone) for C 3 months. In BOOST
INTENSIFY ALL, patients who had been receiv-
ing once- or twice-daily basal insulin, a pre-
mixed insulin, or a self-mixed
insulin ± metformin were eligible. Inclusion
criteria for the two trials were otherwise similar;
patients were eligible for inclusion if they
were C 18 years of age (C 20 for BOOST
INTENSIFY ALL participants in Japan and Tai-
wan), with glycated hemoglobin (HbA1c)
7.0–10.0% (53–86 mmol/mol) and body mass
index (BMI)\ 40 kg/m2 (BOOST INTENSIFY
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PREMIX I) or\35 kg/m2 (BOOST INTENSIFY
ALL). In both trials, patients were excluded if
they had a history of recurrent severe hypo-
glycemia or hypoglycemic unawareness. The
Japanese subgroup was drawn from the overall
population. For this post hoc analysis, all
patients who were aged 65 years or over were
included.
Compliance with Ethics Guidelines
The protocols, protocol amendments, consent
forms, and subject information sheets of the
original BOOST INTENSIFY PREMIX I and
BOOST INTENSIFY ALL trials were reviewed and
approved by health authorities according to
local regulations and by the local independent
ethics committees prior to trial initiation
[31, 32]. The trials were performed in accor-
dance with the Declaration of Helsinki and
good clinical practice [36, 37]. In summary, all
procedures performed in studies involving
human participants were in accordance with
the ethical standards of the institutional and/or
national research committee and with the 1964
Declaration of Helsinki and its later amend-
ments or comparable ethical standards.
Informed consent was obtained from all indi-
vidual participants included in the study.
Assessments and Statistical Analyses
The current analyses present pooled data from
both trials for the elderly subpopulation. The
Fig. 1a–b Trial designs for a BOOST INTENSIFY
PREMIX I (global patient population) [31] and
b BOOST INTENSIFY ALL (pan-Asian patient popula-
tion) [32]. BIAsp 30 biphasic insulin aspart 30, BID twice
daily, BMI body mass index, DPP-4i dipeptidyl peptidase-4
inhibitor, HbA1c glycated hemoglobin, IDegAsp insulin
degludec/insulin aspart, met metformin, n number ran-
domized, OAD oral antidiabetic drug, OD once daily, pio
pioglitazone
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primary endpoint in both trials was change
from baseline in HbA1c after 26 weeks of treat-
ment. A linear regression model (analysis of
covariance) was used to analyze the change in
HbA1c from baseline to end of treatment with
trial, treatment, sex, geographic region, and
antidiabetic treatment at screening as grouping
factors and age and baseline response as
covariates. For individual trial groups, trial is
not included as a fixed effect. Missing data were
accounted for using the last observation carried
forward method. Fasting plasma glucose (FPG)
and insulin dose (log transformed) were ana-
lyzed using the same model.
The number of treatment-emergent con-
firmed hypoglycemic events was analyzed with
a negative binomial regression model, using a
log-link function adjusted for trial, treatment,
sex, geographic region, and antidiabetic treat-
ment at screening as fixed effects, age as
covariate, and the logarithm of the exposure
time as offset.
Hypoglycemia Classification
Confirmed hypoglycemia included severe epi-
sodes (episodes requiring the assistance of
another person to actively administer carbohy-
drate, glucagon, or other resuscitative actions)
and episodes confirmed by plasma glucose
(PG;\ 56 mg/dL [3.1 mmol/L]) or full blood
glucose (\ 50 mg/dL [2.8 mmol/L]) measure-
ments that were handled by the patient him-
self/herself, and could be with or without
symptoms consistent with hypoglycemia. Noc-
turnal hypoglycemia was defined as episodes of
confirmed hypoglycemia that occurred between
00:01 and 05:59 h (inclusive).
Safety
All patients receiving at least one dose of trial
product were included in the safety analysis set.
Safety was assessed using overall confirmed
hypoglycemia and nocturnal hypoglycemia,
based on the Novo Nordisk classification for
hypoglycemia (plasma glucose 56 mg/dL
[\ 3.1 mmol/L]). Adverse events were coded
using the most recent version of Medical Dic-
tionary for Regulatory Activities (MedDRA)
coding (version 13.0 for BOOST INTENSIFY
PREMIX I and version 13.1 for BOOST INTEN-
SIFY ALL).
RESULTS
Baseline Characteristics
The combined analysis comprised 271 patients
(representing 31.2% of the total population
from the two trials), of whom 146 were treated
with IDegAsp twice daily and 125 were treated
with BIAsp 30 twice daily. Japanese patients
comprised the largest subgroup (N = 72, 26.6%
of the analyzed cohort). Baseline characteristics
for the subpopulation of patients aged C
65 years from each trial and from the pooled
data are shown in Table 1. The mean age at
baseline, BMI, duration of diabetes, HbA1c (%;
mmol/mol), and FPG were similar for both
treatment arms in the pooled data. BMI at
baseline was lower in the pan-Asian population
compared with the global population. Duration
of diabetes was longer in the pan-Asian popu-
lation compared with the global population.
Glycemic Control
There were no statistically significant differences
in HbA1c in the combined analysis between
treatment with IDegAsp or BIAsp 30 (estimated
treatment different [ETD, IDegAsp–BIAsp 30]:
-0.02% [- 0.19; 0.15]95% CI, p = 0.8455). A sig-
nificant reduction in FPG was observed with
IDegAsp versus BIAsp 30 (ETD [IDegAsp–BIAsp
30]: - 1.41 mmol/L [- 1.85; - 0.96]95% CI,
p \ 0.0001). Similar results were observed in
Japanese patients, with an ETD (IDegAsp–BIAsp
30) of - 0.01% [- 0.31; 0.29]95% CI, p = 0.9521
for HbA1c and - 1.86 mmol/L [- 2.75;
- 0.97]95% CI, p \0.0001 for FPG (Table 2).
Hypoglycemia
Overall confirmed and nocturnal hypoglycemic
events by classification are shown, by trial
population and for the combined analysis, in
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Table 3. The estimated rate ratios for overall
confirmed and nocturnal confirmed hypo-
glycemia for the combined analysis are shown
in Fig. 2. In the combined analysis, there were
fewer overall confirmed hypoglycemic events
with IDegAsp (1041.18 events/100 patient-years
of exposure [PYE]) compared with BIAsp 30
(1134.40 events/100 PYE), estimated rate ratio
(ERR): 0.92 [0.67; 1.26]95% CI, p = 0.5980. There
were fewer nocturnal hypoglycemic events in
patients treated with IDegAsp compared with
patients treated with BIAsp 30, ERR (IDegAsp/
BIAsp 30): 0.67 [0.39; 1.18]95% CI, p = 0.1676. In
the Japanese patient population, there was a
12% lower rate of overall confirmed hypo-
glycemia with IDegAsp compared with BIAsp
30, ERR: 0.88 [0.47; 1.66]95% CI; p = 0.7026.
There was also a 42% lower rate of nocturnal
hypoglycemia with IDegAsp compared with
BIAsp 30, which was not significant, ERR: 0.58
[0.22; 1.51]95% CI, p = 0.2643, in the Japanese
subpopulation.
Insulin Dose
Mean insulin dose at the end of the trial was
significantly lower for patients treated with
IDegAsp than for patients treated with BIAsp 30,
with an estimated treatment ratio (ETR) of 0.79
[0.73; 0.87]95% CI, p \ 0.0001. Results were
similar and also significant in Japanese patients,
with an ETR of 0.78 [0.65; 0.95]95% CI,
p = 0.0121 (Table 2).
Safety
Overall, 271 patients were included in the safety
analysis set, 146 of whom were in the IDegAsp
treatment arm and 125 were in the BIAsp 30
treatment arm. A slightly higher percentage of
patients reported one or more AE with IDegAsp
versus BIAsp 30 (70.5% vs. 60.8%, respectively).
There were more withdrawals among patients
treated with BIAsp 30 (19.0%) than with
IDegAsp (14.4%), but the majority of the
Table 1 Demographics and baseline characteristics of elderly patients (C 65 years of age) with type 2 diabetes mellitus
included in the analysis
Characteristic BOOST INTENSIFY
PREMIX I (global patient
population)
BOOST INTENSIFY ALL
(pan-Asian patient
population)
Total included in combined
analysis
IDegAsp
BID
BIAsp 30
BID
IDegAsp
BID
BIAsp 30
BID
IDegAsp
BID
BIAsp 30
BID
Full analysis set, n 66 70 80 55 146 125
Males, % 62.1 47.1 50.0 52.7 55.5 49.6
Age, years 70.0 (4.4) 69.5 (3.5) 70.9 (4.3) 70.2 (4.5) 70.5 (4.3) 69.8 (4.0)
BMI, kg/m2 30.0 (4.5) 29.9 (4.8) 24.6 (2.8) 24.6 (3.5) 27.1 (4.5) 27.6 (5.0)
Duration of diabetes,
years
15.8 (7.5) 17.0 (8.3) 20.7 (8.1) 19.2 (8.8) 18.5 (8.2) 18.0 (8.6)
HbA1c, % 8.0 (0.7) 8.1 (0.8) 8.4 (0.8) 8.3 (0.9) 8.2 (0.8) 8.2 (0.8)
HbA1c, mmol/mol 64.1 (7.9) 65.2 (8.7) 68.1 (8.3) 67.7 (9.4) 66.3 (8.3) 66.3 (9.1)
FPG, mg/dL 156.3 (42.0) 151.1 (36.2) 142.6 (44.9) 146.4 (51.7) 148.8 (44.0) 149.0 (43.6)
FPG, mmol/L 8.7 (2.3) 8.4 (2.0) 7.9 (2.5) 8.1 (2.9) 8.3 (2.4) 8.3 (2.4)
Data are mean (SD) unless otherwise stated
BIAsp 30 biphasic insulin aspart 30, BID twice daily, BMI body mass index, FPG fasting plasma glucose, HbA1c glycated
hemoglobin, IDegAsp insulin degludec/insulin aspart, n number of patients, SD standard deviation
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withdrawals were not a result of AEs (Table 4).
The majority of the AEs were considered unli-
kely to be related to trial production in BOOST
INTENSIFY PREMIX I (71% with IDegAsp and
57% with BIAsp 30) and BOOST INTENSIFY ALL
(69% with IDegAsp and 58% with BIAsp 30).
DISCUSSION
This post hoc analysis of a pooled population of
elderly patients demonstrates that treatment
with IDegAsp provides effective glycemic con-
trol consistent with the effects of BIAsp 30. No
statistically significant differences were seen
between the two therapies in HbA1c and in
overall confirmed or nocturnal hypoglycemic
events. Similar findings were observed in the
subanalysis of Japanese patients. Our results are
largely in agreement with those reported for the
overall trial population [33], although the lower
rates of hypoglycemia reported for IDegAsp vs.
BIAsp 30 in the elderly population did not reach
statistical significance. However, mean insulin
dose at the end of the trial was significantly
lower for elderly patients treated with IDegAsp
compared with BIAsp 30. The safety profile was
similar for each treatment.
Hypoglycemia is a major barrier to achieving
glycemic control for anyone with diabetes, but
definitions of hypoglycemia vary between
studies, and this can have a major effect on the
reported incidence [38]. Furthermore, the out-
comes and experience associated with bio-
chemically similar hypoglycemic events can
vary for different patients. Therefore, this anal-
ysis assessed the incidence of hypoglycemia
with IDegAsp when applying the PG threshold
of\ 56 mg/dL (3.1 mmol/L), which is similar to
the threshold that the 2017 Joint Position
Statement of the American Diabetes Association
and the European Association for the Study of
Table 2 Overview of results for the elderly Japanese subpopulation of BOOST INTENSIFY ALL
Characteristic n IDegAsp BID n BIAsp 30 BID IDegAsp–BIAsp 30
HbA1c, (mmol/mol)
Baseline
End of trial
44
44
67.0 (6.5)
53.2 (7.2)
28
28
67.8 (8.6)
53.5 (7.9)
ETD: -0.10 [-3.38; 3.18]95% CI, p = 0.9521
HbA1c, (%)
Baseline
End of trial
44
44
8.3 (0.6)
7.0 (0.7)
28
28
8.4 (0.8)
7.0 (0.7)
ETD: -0.01 [-0.31; 0.29]95% CI, p = 0.9521
FPG, (mg/dL)
Baseline
End of trial
44
44
147.2 (40.6)
92.5 (26.8)
28
28
151.7 (46.0)
125.9 (40.3)
ETD: -33.58 [-49.63; -17.53]95% CI, p \ 0.0001
FPG, (mmol/L)
Baseline
End of trial
44
44
8.2 (2.3)
5.1 (1.5)
28
28
8.4 (2.6)
7.0 (2.2)
ETD: -1.86 [-2.75; -0.97]95% CI, p \ 0.0001
Insulin dose (U)
Baseline
End of trial
43
43
27.0 (13.8)
34.9 (20.3)
28
28
22.8 (11.8)
39.3 (21.7)
ETR: 0.78 [0.65; 0.95]95% CI, p = 0.0121
BIAsp 30 biphasic insulin aspart 30, BID twice daily, CI conﬁdence interval, ETD estimated treatment difference, ETR
estimated treatment ratio, FPG fasting plasma glucose, HbA1c glycated hemoglobin, IDegAsp insulin degludec/insulin aspart,
n number of patients
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Diabetes recommends that all studies should
report, as it is considered to be clinically sig-
nificant and associated with an unequivocal
hypoglycemic episode [39]. The findings pre-
sented here show that IDegAsp results in a lower
rate of hypoglycemia compared with BIAsp 30
when using this threshold in the elderly sub-
population. As hypoglycemia is of particular
concern in the elderly, the results of this post
hoc analysis are reassuring.
An important limitation of this analysis was
the relatively low number of elderly patients,
and the low number of hypoglycemic episodes,
Table 3 Overall conﬁrmed and nocturnal conﬁrmed hypoglycemic episodes for elderly patients (C 65 years of age) with
type 2 diabetes mellitus
BOOST INTENSIFY PREMIX I (global patient population)
IDegAsp BID BIAsp 30 BID
n (%) E R n (%) E R
Conﬁrmed 50 (75.8) 332 1093.64 52 (74.3) 407 1367.34
Nocturnal conﬁrmed 16 (24.2) 20 65.88 25 (35.7) 53 178.06
BOOST INTENSIFY ALL (pan-Asian patient population)
IDegAsp BID BIAsp 30 BID
n (%) E R n (%) E R
Conﬁrmed 62 (77.5) 418 1156.10 40 (72.7) 253 1031.69
Nocturnal conﬁrmed 19 (23.8) 58 160.42 19 (34.5) 37 150.88
BOOST INTENSIFY ALL (Japanese subpopulation)
IDegAsp BID BIAsp 30 BID
n (%) E R n (%) E R
Conﬁrmed 31 (70.5) 249 1246.54 22 (78.6) 187 1441.57
Nocturnal conﬁrmed 11 (25.0) 30 150.19 12 (42.9) 29 223.56
POOLED ANALYSIS (global patient population)
IDegAsp BID BIAsp 30 BID
n (%) E R n (%) E R
Conﬁrmed 112 (76.7) 750 1127.59 92 (73.6) 660 1215.72
Nocturnal conﬁrmed 35 (24.0) 78 117.27 44 (35.2) 90 165.78
Conﬁrmed hypoglycemia: patient unable to treat himself/herself and/or has a recorded plasma glucose\ 56 mg/dL
(3.1 mmol/L)
BIAsp 30 biphasic insulin aspart 30, BID twice daily, E number of events, IDegAsp insulin degludec/insulin aspart, n number
of patients, R event rate per 100 patient-years of exposure
Fig. 2 Estimated rate ratios for overall conﬁrmed and
nocturnal conﬁrmed hypoglycemia. BIAsp 30 biphasic
insulin aspart 30, CI conﬁdence interval, IDegAsp insulin
degludec/insulin aspart
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which prohibited statistical analysis of the
incidence of severe hypoglycemia. Nonetheless,
our findings show that IDegAsp results in a
numerically lower rate of hypoglycemia com-
pared with BIAsp 30, and that there were no
additional safety signals in this population that
might require further investigation.
CONCLUSION
In conclusion, the analytical results for elderly
patients with T2D included in the phase 3
BOOST INTENSIFY PREMIX I and BOOST
INTENSIFY ALL studies are consistent with
those for the overall trial populations, and the
low rates of hypoglycemia are reassuring, sug-
gesting that there is no need for special pre-
cautions when using IDegAsp twice daily in
elderly patients—it should be administered in a
similar manner to how it is administered in
younger adults.
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